Cassava Sciences Faces Critical Juncture After Alzheimer’s Trial Failure

The publication of peer-reviewed final data from two pivotal Phase 3 trials has dealt a definitive blow to Cassava Sciences’ lead Alzheimer’s drug candidate, Simufilam. The findings, now available in the Journal of Prevention of Alzheimer’s Disease, confirm the therapy’s failure and cast significant doubt on the company’s future trajectory, sending its shares to near annual lows.

Data from the studies, which involved more than 1,900 patients collectively, show Simufilam missed all its primary and secondary efficacy endpoints. The drug proved no better than a placebo at slowing cognitive decline in patients with Alzheimer’s disease. While the treatment maintained a favorable safety profile, the absence of Read more...